

## REVIEW ARTICLE

# Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions

Q1 MICHAEL J. PELUSO, JOANNA DONATELLI, and TIMOTHY J. HENRICH

SAN FRANCISCO, CALIFORNIA

The current era of COVID-19 is characterized by emerging variants of concern, waning vaccine- and natural infection-induced immunity, debate over the timing and necessity of vaccine boosting, and the emergence of post-acute sequelae of SARS-CoV-2 infection. As a result, there is an ongoing need for research to promote understanding of the immunology of both natural infection and prevention, especially as SARS-CoV-2 immunology is a rapidly changing field, with new questions arising as the pandemic continues to grow in complexity. The next phase of COVID-19 immunology research will need focus on clearer characterization of the immune processes defining acute illness, development of a better understanding of the immunologic processes driving protracted symptoms and prolonged recovery (ie, post-acute sequelae of SARS-CoV-2 infection), and a growing focus on the impact of therapeutic and prophylactic interventions on the long-term consequences of SARS-CoV-2 infection. In this review, we address what is known about the long-term immune consequences of SARS-CoV-2 infection and propose how experience studying the translational immunology of other infections might inform the approach to some of the key questions that remain. (Translational Research 2021; ■■:■■-■■)

**Abbreviations:** AIM assay = activation induced marker; COVID-19 = coronavirus disease 2019; ELISpot assay = Enzyme-linked immunospot; ICS = intracellular cytokine staining; IL = interleukin; MAIT cell = mucosa-association invariant T; PASC = post-acute sequelae of SARS-CoV-2 infection; RBD = receptor-binding domain; SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2; SOT = Solid organ transplant

## OVERVIEW

Many questions remain regarding the immunologic consequences of SARS-CoV-2 infection. While initial

studies were crucial in demonstrating that most individuals develop long-term humoral and cell-mediated immunity to infection with the virus, the current era of COVID-19 is characterized by emerging variants of concern, waning vaccine- and natural infection-induced immunity, debate over the timing and necessity of vaccine boosting, and the emergence of post-acute sequelae of SARS-CoV-2 infection (PASC). As millions of individuals worldwide continue to become infected, there is an ongoing need for research to promote understanding of the immunology of both natural infection and prevention. In this review, we address what is known about the long-term immune consequences of SARS-CoV-2 infection and propose how experience studying the translational immunology of other

From the Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, California; Division Experimental Medicine, University of California, San Francisco, California.

Submitted for Publication October 11, 2021; received submitted November 2, 2021; accepted for publication November 5, 2021.

Reprint requests: Timothy Henrich, Division of Experimental Medicine, Building 3, 1001 Potrero Ave, San Francisco, CA, 94044. e-mail: [timothy.henrich@ucsf.edu](mailto:timothy.henrich@ucsf.edu).

1931-5244/\$ - see front matter

© 2021 Published by Elsevier Inc.

<https://doi.org/10.1016/j.trsl.2021.11.006>

infections might inform the approach to some of the key questions that remain.

## LONG-TERM PROTECTIVE IMMUNITY FOLLOWING INFECTION

Most individuals with SARS-CoV-2 infection develop robust and persistent immunologic responses following natural infection, and as of the time of this review, many studies have characterized the humoral<sup>1-23</sup> and cell-mediated<sup>19, 24-33</sup> immune responses during convalescence for periods of up to 1 year. While the magnitude of the immune response to natural infection is at least in part determined by the severity of the illness,<sup>3, 6,7,15,28,30</sup> the predictors of the duration of natural immunity are not fully understood and may be determined by a variety of clinical and measurement factors.<sup>15,18</sup> Despite this complexity, there is general consensus that, in most cases, natural immunity persists for up to at least 8 months. Despite the observation that antibody levels may wane over time, several studies have now demonstrated persistence of virus-specific lymphocytes over 12 months following natural infection by various intracellular cytokine staining (ICS), activation induced marker (AIM), and EliSpot assays. These assays quantify T cell cytokine expression (ICS/EliSpot) or surface markers of T cell activation (AIM) following antigenic stimulation with various virus-specific peptide pools. For example, the percentage of virus-specific CD8 and CD4 T cells as measured by ICS or AIM range from approximately 0.01%–10% during this extended time period across multiple studies,<sup>25,26,28,29,31,32</sup> with the median or mean percentage typically <1%. Spot forming cells/units in ELISpot assays tend to range from 10 to >1,000 in response to SARS-CoV-2 peptides, including HLA-restricted pools.<sup>27,34</sup> These responses wane slowly over time in all assays depending on initial disease severity and various clinical factors but can typically be detected across a range of virus gene regions (eg, Spike, Nucleocapsid, Membrane).

These immunologic findings have been borne out by the clinical observation that reinfection with similar viral variants was relatively uncommon in the first year of the pandemic, with some exceptions.<sup>35</sup> During the first year of the pandemic, re-infection seemed exceedingly rare and fewer than 50 cases were reported in the literature,<sup>35</sup> although the true burden of re-infection is difficult to estimate given the scale of the pandemic, the high proportion of asymptomatic infections, and the variability in access to testing. While there was initially hope that those with prior SARS-CoV-2 infection would aid efforts toward herd immunity and could be at lower risk for re-infection, more recent studies have

demonstrated that natural immunity within a population itself is likely insufficient to fully protect against reinfection, particularly with novel variants of concern.<sup>36</sup> The study of long-term natural immunity has been complicated by the relatively widespread rollout of highly efficacious vaccines with inconsistent uptake across demographic and geographic locales in addition to the recent authorization or approval of booster vaccine doses across the United States and Europe.

## BREADTH AND DEPTH OF T CELL IMMUNE RESPONSES AND CROSS-REACTIVITY OTHER CORONAVIRUSES

Data regarding the breadth of SARS-CoV-2-specific T cell immune responses following natural infection and the potential for cross-reactivity with other human beta-coronaviruses are rapidly evolving and were reviewed by Grifoni and colleagues.<sup>37</sup> Thus far, over 1400 unique CD8 and CD4 T cell epitopes have been identified,<sup>37,38</sup> although only a handful of antigens comprise >85% of these. Interestingly, immunodominant regions of the spike protein for CD4 T cells are relatively limited, whereas distribution for CD8 cells are more homogeneous.<sup>37</sup> Nonetheless, a prior study estimates that an individual may recognize 17 different CD8 and 19 different CD4 immunologically important epitopes.<sup>38</sup> In addition, we and others have shown that SARS-CoV-2 specific CD4 T cell responses, and to a much lesser extent CD8 T cell responses, are significantly correlated with antibody responses including total levels and neutralization capacity.<sup>30,39,40</sup> CD4 and CD8 T cells also appear to play unique roles in clinical disease, or respond differently to natural infection, and it is important to impart that these cells play different roles in immune responses to infection and should not be thought of as a unified T cellular response. For example, we and others have demonstrated that the magnitude of virus-specific CD4 T cells appears to correlate with initial disease severity and with levels and neutralization capacity of antibody responses.<sup>25,30,41,42</sup> These associations were not consistently observed with CD8 T cell responses in our study, which appear to be influenced by other clinical factors. For example, we previously reported that pre-existing lung disease is independently associated with higher long-term SARS-CoV-2-specific CD8+, but not CD4+, T cell responses. Regardless of the differences between CD4 and CD8 T cell responses, there is now data emerging that virus-specific T cell reactivity is not significantly disrupted by viral variants, such as Delta.<sup>43,44</sup>

There is also data emerging that some individuals may have cross-reactive T cell responses to other human beta-coronaviruses with detectable responses to

those without a history of known infection.<sup>25,28,41,45,46</sup> Some of these responses may be a result of occult, asymptomatic prior SARS-CoV-2 infection that led to aborted or rapidly waning antibody levels,<sup>29,47</sup> but data exist suggesting that pre-existing memory responses from endemic, less-pathogenic coronaviruses or other pathogens occur in some individuals.<sup>34,48</sup> Interestingly, pre-existing cross-reactive T cell responses may be better detected by assays that measure the capacity for T cells to proliferate in response to SARS-CoV-2 Spike protein stimulation *ex vivo* rather than by intracellular or cell surface markers of response.<sup>49</sup> Regardless, it is poorly understood to what extent or how long pre-existing cross-reactive immunity may protect from acute infection or modulate disease severity and the development and persistence of post-acute sequelae and further study is urgently needed.

### VACCINE INDUCED ANTIBODY AND T CELL RESPONSES

Initial vaccine trials predominantly enrolled healthy adults, and those currently approved or pending approval for use in the United States and Europe (Pfizer/BioNTech BNT162b1, AstraZeneca ChadOx1, Moderna mRNA-1273, Janssen Ad26.COVS2, Novavax NVX-CoV2373) lead to robust antibody binding and neutralization titers.<sup>50</sup> Antibody responses generally mirror protection from asymptomatic through severe disease, hospitalization and death. However, efficacy has been shown to wane over time leading various regulatory agencies in Europe and the United States to approve or authorize boosters or third doses for adults,<sup>51-55</sup> with or without underlying immunomodulatory conditions or belonging to risk groups. Despite waning antibody titers and increased cases of mild infection, vaccines continue to protect against severe disease and hospitalization for up to 6 months.<sup>51-55</sup> As of now, vaccines remain active against the predominant circulating strains of SARS-CoV-2, and variants that may be more resistant to vaccination, such as Mu, appear to have a replication disadvantage compared with the widely circulating delta variant. Whereas levels of nasopharyngeal shedding have been reported to be similar in persons who acquired infection after full vaccination compared with those who were previously unvaccinated, the duration of viral shedding and symptoms are significantly shorter, and infection may be more compartmentalized to non-shedding tissues.<sup>56</sup> Further research is warranted to more precisely determine the impact of vaccination on infectivity of breakthrough infection. Regardless, vaccine use has had a

dramatic positive effect on reducing morbidity, mortality and community spread of SARS-CoV-2.

Data on T cell responses from vaccine trials are more sparse, and systematic study of adaptive cellular responses varied across initial studies (as reviewed elsewhere<sup>50</sup>). A majority of approved or authorized vaccines, however, have demonstrated development of CD4, CD8 or total T cell responses as measured by spot forming colonies per 10<sup>6</sup> cells in EliSpot assays (40 to >2600 spot forming colonies). Data on the decay of T cell responses following vaccination over time are currently lacking, and it is not known what role vaccine-elicited virus-specific T cell responses play in preventing primary infection or modulating the course of acute and post-acute disease.

To date, the immunologic response prior to SARS-CoV-2 vaccination has been characterized for over 12 months.<sup>57,58</sup> The current surge of the delta variant of SARS-CoV-2 globally has revealed that vaccine-induced immunity might be insufficient to prevent infection and more severe disease in many cases. Furthermore, the duration for which vaccine-induced immunity can protect against severe disease and hospitalization remains unclear, although boosting is likely to significantly extend the duration of protection.

### IMMUNITY IN IMMUNOCOMPROMISED INDIVIDUALS

It is now well established that antibody and T cell responses can be severely impaired following vaccination,<sup>59</sup> and to a lesser extent, natural infection,<sup>60-62</sup> in immunocompromised individuals, including solid organ transplant (SOT) recipients, cancer patients, and others receiving immunomodulatory medications for various conditions. For example, there is growing evidence that SOT recipients do not develop detectable antibody levels or measurable neutralizing capacity following two-dose vaccination,<sup>63-68</sup> and current clinical experience demonstrates higher rates of post-vaccine infection and hospitalizations in this population. An additional third or even fourth dose appears to increase antibody responses, however.<sup>69,70</sup> Patients with cancer, especially those with hematological malignancies on cytoreductive or anti-B cell therapies and certain rheumatologic diseases also exhibit reduced antibody responses to vaccination,<sup>71-73</sup> albeit to a lesser degree than those who have received SOT but may experience high rates of vaccine breakthrough.<sup>74</sup> Various medications that have anti-proliferative mechanisms of actions (such as mycophenolic acid derivatives) may be associated with more impaired antibody, B and T cell responses. As above, anti-B cell agents and systemic corticosteroids impact

antibody responses and memory B cell responses and combinations of immunomodulatory agents are likely to have more profound and lasting negative impacts on these immune responses.<sup>64,65,67,75-77</sup>

T cell responses are also impaired in the setting of immunosuppressive medications and diseases, but data are now emerging that these responses are somewhat discordant with antibody responses following vaccination. For example, nearly half of kidney transplant recipients in one study that did not develop antibody responses following vaccination had detectable SARS-CoV-2-specific T cell responses.<sup>64</sup> Whether or not these T cell responses are protective, as discussed above, is not known and requires further study. However, recent data show that persons that receive anti B cell therapy (eg, anti-CD20 for multiple sclerosis) have a paradoxical increase in SARS-CoV-2-specific CD8 T cell responses, despite significant impairment of humoral responses.<sup>75,78-82</sup> The increase in CD8 T cell responses may reflect an immune compensatory mechanism,<sup>78,83,84</sup> but it is still not clear what role virus-specific CD8 T cells have in protection from infection or modulation of disease severity. It is also interesting to note that despite the potential for increased CD8 T cell responses, individuals with impaired humoral responses have increased risk of more severe infection.<sup>78,85</sup>

Immunity in other immunocompromised individuals, such as those living with HIV infection, is more variable. Recent work has suggested a lower magnitude humoral and cell-mediated immune responses<sup>86-88</sup> or shorter duration of the antibody response in comparison to the general population,<sup>89</sup> although both observations require further study. Recent studies suggest that the immune response following vaccination is equal amongst PLWH and the general population<sup>90</sup> and in comparison to those with other immunocompromising conditions,<sup>91</sup> but further work is needed to confirm these findings given the global concern for sustained immunity to SARS-CoV-2 and the known poorer responses to immunization for other infections among PLWH.<sup>92-97</sup> This includes suboptimal responses to vaccination to prevent against yellow fever,<sup>93,94</sup> Hepatitis B,<sup>96</sup> influenza,<sup>95</sup> polio, diphtheria, and tetanus.<sup>97</sup> It is likely that inadequate CD4+ T cell immune reconstitution, chronic inflammation, and T cell exhaustion underlie these observations,<sup>93</sup> and careful studies will be needed to understand how HIV and COVID-19 vaccination durability overlap.

#### HUMAN INFLAMMATORY RESPONSES IN COVID-19

COVID-19 can lead to profound inflammatory responses in acute infection and to increased levels of various cytokines, such as TNF- $\alpha$ , IL-6, and IP10, which

are associated with more severe disease and organ damage.<sup>98-103</sup> Especially among those hospitalized with COVID-19, inflammation during the acute and early post-acute phase of infection has been associated with poor outcomes.<sup>104-110</sup> In addition, many individuals present with profound lymphopenia, including a marked decrease in circulating NK, CD8 and CD4 T cells, including helper & regulatory T cells.<sup>98-103</sup> Lower numbers of circulating monocytes, eosinophils and basophils have also been observed. In contrast, leukocyte counts tend to be higher in patients with severe clinical manifestations.<sup>111,112</sup> Despite lymphopenia in more severe SARS-CoV-2 infection, increased frequency of T cells responding to various antigens such as, Spike, Nucleocapsid, membrane, and accessory (functional) protein (eg, ORF 1ab) peptide sequences develop within the weeks following infection.<sup>29</sup> Although lymphocyte counts return and virus-specific adaptive immunity develop early during clinical recovery, increased markers of T cell exhaustion and reduced functional diversity of T cell subsets have been reported in the early convalescent period.<sup>98,99,113,114</sup>

Emerging data suggest that inflammation related to acute SARS-CoV-2 infection can persist for weeks or even months.<sup>115,116</sup> One study found that convalescent plasma donors with prior COVID-19 demonstrated elevations in certain markers of inflammation compared to historical controls, even though they presumably felt well enough to donate plasma.<sup>115</sup> These markers include interferon (IFN)-gamma, certain interleukin (IL) proteins (eg, IL-12p70, IL-13, IL-1 $\beta$ , IL-2, IL-4, IL-5, IL-33), and monocyte chemoattractant protein (MCP)-1 and suggest ongoing immune activation. Another study of a large cohort of individuals hospitalized with asymptomatic, mild, and severe disease showed that individuals who recovered from COVID-19 had elevated levels of proinflammatory and angiogenic markers at 6 months in comparison to healthy controls.<sup>116</sup> There is an ongoing need for work exploring the clinical implications of persistent inflammation following SARS-CoV-2; while such elevations are clearly significant in chronic infections like HIV,<sup>117,118</sup> this is less well understood for acute infections like SARS-CoV-2 which is not thought to persist over the long-term.

#### IMMUNOLOGIC AND INFLAMMATORY MANIFESTATIONS OF POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION (PASC)

Recently, there has been recognition that a significant proportion of individuals recovering from SARS-CoV-2 infection experience new or persistent

439 symptoms that did not pre-date their infection.<sup>119-122</sup>  
440 Investigation into PASC is only just beginning, and the  
441 pathophysiology of the condition is thus far entirely  
442 unknown. While well-designed epidemiologic studies  
443 are beginning to identify certain risk factors for PASC,  
444 including female sex, older age, severity of initial  
445 infection, number of symptoms during acute illness,  
446 and sociodemographic factors, the condition remains  
447 poorly understood.<sup>119-122</sup>

448 One major question is whether PASC is an immuno-  
449 logic phenomenon, either from long-term sequelae fol-  
450 lowing an immunologic insult that occurs early in the  
451 course of the infection (ie, a “hit and run” mechanism)  
452 or related to an ongoing immunologic or other pertur-  
453 bation, potentially in the setting of ongoing viral persis-  
454 tent in tissue. So far, the clues have been limited. A  
455 handful of studies have identified higher levels of bind-  
456 ing or neutralizing antibodies in those with  
457 PASC,<sup>122,123</sup> suggesting that persistent symptoms  
458 could be a manifestation of more severe illness (which  
459 is known to be associated with higher antibody levels  
460 and correlated with higher risk of developing PASC) or  
461 possibly persistent immune stimulation.<sup>14</sup> Other studies  
462 have found that the humoral response appears *lower*  
463 among those with persistent symptoms.<sup>124-126</sup> For  
464 example, ongoing viral shedding in the gut is associ-  
465 ated with lower RBD-specific antibodies,<sup>124</sup> suggesting  
466 suboptimal immune responses may result in persistent  
467 viral antigen. Furthermore, a handful of studies have  
468 correlated PASC with lower SARS-CoV-2 specific  
469 antibody responses,<sup>126</sup> and have shown that those with  
470 lower titres during early recovery might be more likely  
471 to have persistent symptoms. Cellular immune studies  
472 are limited and have thus far not revealed obvious dif-  
473 ferences, although our recent work has suggested  
474 lower<sup>126</sup> or differential decay in the magnitude of  
475 SARS-CoV-2 specific CD8+ T cell responses among  
476 those with PASC.<sup>30</sup> While intriguing, the precise impli-  
477 cations of this finding is not known, and could either  
478 represent a more exhausted pool of viral-specific cells  
479 that develop over time or other immune dysregulation  
480 or detrimental systemic inflammation leading to decay  
481 in the frequency of these CD8 T cells. Understanding  
482 the relationship between immune responses during  
483 early recovery and the persistence of PASC symptoms  
484 could guide diagnostic or therapeutic decision making  
485 for millions of individuals recovering from COVID-19.

486 Studies that have evaluated persistent inflammation  
487 have suggested potential elevations in  
488 biomarkers,<sup>116,127</sup> although no clear immunologic  
489 pathways have yet to be consistently implicated. We  
490 recently demonstrated that during early recovery (ie,  
491 one to two months after initial infection), those who  
492 went on to develop PASC generally had higher levels

493 of biomarkers including significant elevations in circu-  
494 lating TNF-alpha and IP-10, and a trend towards higher  
495 IL-6 levels. During late recovery (4 months following  
496 infection), levels of TNF-alpha and IP-10 levels  
497 decayed and converged with levels in participants  
498 without PASC, whereas IL-6 elevations became more  
499 pronounced. These differences tended to be more pro-  
500 nounced among those with a greater number of PASC  
501 symptoms suggesting that PASC is associated with  
502 increased immune activation over time, which may  
503 underlie some symptoms which persist for more than 3  
504 months following SARS-CoV-2 infection. IL-6 eleva-  
505 tions may result from immune cell activation and sig-  
506 naling, degradation of gut mucosal integrity and  
507 translocation of bacterial and other infectious agents, B  
508 cell activation, among many other processes.<sup>117,128,129</sup>  
509 Further characterization of such biological pathways  
510 and the processes that might drive them could lead to  
511 the identification of therapeutic targets for those  
512 experiencing PASC. In a prior study, we did not  
513 observe differences in markers of aberrant blood clot-  
514 ting, such as D-Dimer in those with and without persis-  
515 tent symptoms, despite disorders of hemostasis  
516 contributing to some individuals with severe COVID-  
517 19.<sup>30</sup> However, further study is certainly warranted  
518 given sample size limitations and the lack of a standard  
519 working definition of PASC.

520 Aberrant autoimmune responses are present during  
521 acute COVID-19 and have been proposed as a potential  
522 underlying etiology of PASC,<sup>130-132</sup> and recent study  
523 showed that over 40% of patients in a longitudinal study  
524 have positive antinuclear antibody (ANA) titers >1:160  
525 12 months following infection.<sup>133</sup> A majority of the  
526 cohort reported PASC symptoms and the number of  
527 symptoms reported were higher in those with a positive  
528 ANA. In our long-term COVID-19 cohort, however, we  
529 were unable to detect positive ANAs in any of 49 partici-  
530 pants approximately 4 months after initial infection and 3  
531 of 69 participants 8 months after acute infection, which is  
532 similar to the percentage of people in the general popula-  
533 tion without known autoimmune disease that have detect-  
534 able ANAs. Our cohort included individuals with and  
535 without PASC, including those with >20 symptoms 8  
536 months after initial infection and perturbation of activities  
537 of daily life.<sup>134</sup> As a result, further studies of potential  
538 autoimmune mechanisms behind PASC are needed in  
539 order to understand these disparate findings.

540 Finally, the alterations of both inflammation and  
541 immune responses in the setting of convalescent  
542 COVID-19 may also influence future risk of various  
543 conditions such as cardiovascular, pulmonary and neu-  
544 rological diseases. Unfortunately, time will be needed  
545 to understand the longer impact of SARS-CoV-2 infec-  
546 tion more fully beyond persistent symptoms.

## TISSUE PERSISTENCE OF SARS-COV-2 INFECTION: A POTENTIAL MECHANISM FOR PASC?

It is well established that immunocompromised individuals are capable of shedding SARS-CoV-2 RNA from oral/nasopharyngeal tissues months after acute infection, and novel variants may have arisen in such individuals under the setting of partial immune pressure.<sup>135,136</sup> However, RNA shedding usually resolves within a month in immunocompetent patients,<sup>137</sup> and we recently observed no persistent RNA shedding in convalescent COVID-19 patients who exhibit PASC approximately 4 months after initial infection.<sup>30</sup> Despite this, there has been limited but intriguing data suggesting that SARS-CoV-2 proteins can be identified in gut tissue months after initial infection.<sup>14</sup> If SARS-CoV-2 remains transcriptionally and/or translationally active in various tissue reservoirs following clearance from naso-pharyngeal tissues, this could represent a potential mechanism underlying the development and maintenance of PASC.<sup>138</sup> There is also data emerging that COVID-19 may lead to intestinal damage and microbial translocation.<sup>139</sup> In chronic infections, such as Human Immunodeficiency Virus (HIV), persistence of virus in gut-associated mucosal tissue leads to gut barrier dysfunction and bacterial/fungal translocation that may lead to elevated markers of immune activation (including IL-6) and inflammation, even in those on suppressive antiretroviral therapy.<sup>128</sup> Furthermore, elevations in IL-6 and other inflammatory markers in the setting of chronic HIV infection are associated with worse clinical outcomes,<sup>140-142</sup> and the longer-term clinical impact of persistent IL-6 elevations identified in our PASC cohort requires further investigation.

Although the mechanisms of PASC are not known, the current thinking is that PASC is a multifactorial process that manifests in diverse clinical and demographic phenotypes. In addition, there is yet to be a standard working definition of PASC and objective phenotypes have yet to be determined. As a result, studying the pathophysiological basis of PASC is going to be challenging and require large numbers of study participants with well curated control groups.

## LEVERAGING THE STUDY OF OTHER CHRONIC INFECTIONS TO UNDERSTAND POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION

The infectious disease research community has developed tools over the last two decades that can be leveraged to support research into duration of immunity and immunologic consequences following SARS-CoV-2 infection. Decades of research in chronic viral

infections, such as HIV as mentioned above, all show that tissue persistence and ongoing inflammation and immune activation can lead to increased morbidity across multiple organ systems. In addition, other chronic viral infections, such as CMV, may lead to long-term inflammation in those with various immune suppressing conditions such as HIV and organ transplantation and increases risk of cardiovascular disease through chronic immune dysregulation,<sup>143-147</sup> and tools have been developed to study tissue-based disease that can be applied to the long-term pathogenesis of COVID-19. Although SARS-CoV-2 is predominately thought of as a respiratory illness, viral receptors, such as ACE2, can be found throughout various tissues in the body, including endovascular tissue and many organ systems.<sup>148-150</sup> Given data hinting at potential viral persistence in gut tissues, many of the potential drivers of PASC could require tissue investigation for meaningful in-depth mechanistic studies.

First, there is an urgent need to understand the long-term immunological and inflammatory impact of SARS-CoV-2 infection in mucosal, gastrointestinal and respiratory tissues. Whereas procedures such as bronchoalveolar lavage can be relatively easy in patients requiring mechanical ventilation for diagnostics or therapeutics, invasive or semi-invasive sampling in the setting of convalescent disease presents greater challenges. Although challenging, the HIV research community has developed a wide range of translational research tools to study viral persistence and immune and inflammatory responses in various mucosal, lymphoid and other tissues which can be applied to the study of COVID-19 and PASC. For example, gut tissue biopsies and lymph node sampling are routinely performed in the clinical and translational HIV research settings, and the study of these tissues have revealed much information on how HIV persists in the setting of suppressive antiretroviral therapy over time and how immune responses (or lack thereof) interact with infected cells.<sup>151-161</sup> In addition, in situ study of viral infection within an anatomic histological context has proved critical in elucidating the burden of infection and impact on immune and inflammatory responses.<sup>153,162-165</sup> In addition to the gastrointestinal studies as discussed above, studies of COVID-19 are now emerging examining the role of T and B cell memory responses in various tissues (eg, lung-associated lymph nodes in adults or tonsillar tissue in children) and mucosa-association invariant T cells in lower airways. It is likely that analysis of human nasopharyngeal, respiratory, lymph node, gut and vascular endothelium will be necessary to fully understand the long-term immune and inflammatory implications of COVID-19. Given the challenges of studying tissues

that are not routinely accessible to clinical sampling, such as the brain, heart, liver, spleen, deeper lymph node chains, to name just a few, non-invasive

**Table I.** Translational science questions related to long-term immunologic consequences of COVID-19

|   |
|---|
| Humoral and Cellular Immunology   |
| What is the role of T cells in preventing or mitigating the severity of acute infection or re-infection in those with prior SARS-CoV-2 infection or vaccination?  |
| At what point following infection or vaccination is protection from hospitalization and severe illness lost? At what point is protection from reinfection lost?   |
| How does post-infection immunity compare with post-vaccine immunity? How does this immunity compare across emerging variants of concern?  |
| What is the functional half-life of SARS-CoV-2-specific T cells and amnestic potential following infection or vaccination?  |
| How do novel SARS-CoV-2 therapeutics, including antivirals and immunomodulatory agents, affect long-term immunity following natural infection?  |
| Are the compensatory T cell responses observed in immunocompromised patients with impaired humoral immunity following vaccination protective?   |
| Mucosal Immunity  |
| What are the key factors in determining the presence and duration of protective mucosal immunity?   |
| How does immune memory differ between what has been observed in peripheral blood with various tissues (eg, mucosal and organized lymphoid tissues, lower respiratory tract, etc.)   |
| What is the role of secretory and circulating IgA antibodies?   |
| Post-Acute Sequelae of SARS-CoV-2 Infection   |
| Are there immune mechanisms active during acute infection that predict the development of post-acute sequelae of SARS-CoV-2 infection (PASC)?   |
| Are there immune mechanisms that are initiated during the recovery phase (ie, after acute infection has resolved) that are associated with PASC?  |
| If immune mechanisms are found to underlie PASC, can we distinguish persistent immune perturbations from the sequelae of so-called "hit-and-run" mechanisms?  |
| Does SARS-CoV-2 antigen persist beyond the period of mucosal viral shedding, either in the form of replication-competent or non-replication-competent virus? If so, at what body sites?                                     |
| Do inadequate or excessive immune responses (including autoimmune) contribute to PASC?  |
| If immune mechanisms drive PASC, are there interventions which can prevent or treat PASC symptoms?  |
| Will PASC lead to increased risk of cardiovascular or neurologic diseases over time?  |
| Quantifying Tissue SARS-CoV-2 Burden and Sequelae   |
| What tissue-based measurements will be informative in determining whether SARS-CoV-2 genetic material or protein persist in tissues? What measurements will be acceptable in those who have entered the convalescent phase? |
| Are there non-invasive methods of measuring whole-body immune responses or inflammation in the setting of SARS-CoV-2 infection?   |

technologies to determine the burden of SARS-CoV-2 infection and short- and long-term immune and inflammatory sequelae are urgently needed.

## CONCLUSION

SARS-CoV-2 immunology is a rapidly changing field, with new questions arising as the pandemic continues to grow in complexity. The next phase of COVID-19 immunology research will focus on clearer characterization of the immune processes defining acute illness, development of a better understanding of the immunologic processes driving protracted symptoms and prolonged recovery (ie, PASC), and a growing focus on the impact of therapeutic and prophylactic interventions on the long-term consequences of SARS-CoV-2 infection.

## UNCITED LINKS

Table I

## ACKNOWLEDGMENTS

T. J. H is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grant number [3R01AI141003-03S1](#) to T. J. H.). M. J. P. is supported by the National Institutes of Health ([T32 AI60530-12](#)) and by the UCSF Resource Allocation Program. T. J. H. receives grant support from Merck and Co. M. J. P. and J. D. report no conflicts of interest.

Conflicts of Interest: All authors have read the journal's policy on conflicts of interest and the authorship agreement.

## REFERENCES

- Seow J, Graham C, Merrick B, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. *Nat Microbiol* 2020;5:1598–607.
- Long Q-X, Tang X-J, Shi Q-L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* 2020;26:1200–4.
- Gudbjartsson DF, Norddahl GL, Melsted P, et al. Humoral immune response to SARS-CoV-2 in Iceland. *N Engl J Med* 2020;383:1724–34.
- Naaber P, Hunt K, Pesukova J, et al. Evaluation of SARS-CoV-2 IgG antibody response in PCR positive patients: Comparison of nine tests in relation to clinical data. *PLoS One* 2020;15:e0237548.
- Chen Y, Zuiani A, Fischinger S, et al. Quick COVID-19 healers sustain anti-SARS-CoV-2 antibody production. *Cell* 2020;183:1496–507, e16.
- Chen X, Pan Z, Yue S, et al. Disease severity dictates SARS-CoV-2-specific neutralizing antibody responses in COVID-19. *Signal Transduct Target Ther* 2020;5:180.

7. Kowitdamrong E, Puthanakit T, Jantarabenjakul W, et al. Antibody responses to SARS-CoV-2 in patients with differing severities of coronavirus disease 2019. *PLoS One* 2020;15:e0240502.
8. Lei Q, Li Y, Hou H-Y, et al. Antibody dynamics to SARS-CoV-2 in asymptomatic COVID-19 infections. *Allergy* 2020. <https://doi.org/10.1111/all.14622>.
9. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. *Clin Infect Dis* 2020;71:2027–34.
10. Ibarrodo FJ, Javier Ibarrodo F, Fulcher JA, et al. Rapid decay of anti-SARS-CoV-2 antibodies in persons with mild Covid-19. *N Engl J Med* 2020;383:1085–7. <https://doi.org/10.1056/nejmc2025179>.
11. Muecksch F, Wise H, Batchelor B, et al. Longitudinal serological analysis and neutralizing antibody levels in coronavirus disease 2019 convalescent patients. *J Infect Dis* 2021;223:389–98. <https://doi.org/10.1093/infdis/jiaa659>.
12. Lau EHY, Tsang OTY, Hui DSC, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun* 2021;12. <https://doi.org/10.1038/s41467-020-20247-4>.
13. Iyer AS, Jones FK, Nodoushani A, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. *Sci Immunol* 2020;5:eabe0367. <https://doi.org/10.1126/sciimmunol.abe0367>.
14. Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* 2021. <https://doi.org/10.1038/s41586-021-03207-w>.
15. Peluso MJ, Takahashi S, Hakim J, et al. SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay. *Sci Adv* 2021;7. <https://doi.org/10.1126/sciadv.abh3409>.
16. Chia WN, Zhu F, Ong SWX, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. *Lancet Microbe* 2021;2:e240–9.
17. L'Huillier AG, Meyer B, Andrey DO, et al. Antibody persistence in the first 6 months following SARS-CoV-2 infection among hospital workers: a prospective longitudinal study. *Clin Microbiol Infect* 2021. <https://doi.org/10.1016/j.cmi.2021.01.005>.
18. Di Germanio C, Simmons G, Kelly K, et al. SARS-CoV-2 antibody persistence in COVID-19 convalescent plasma donors: Dependency on assay format and applicability to serosurveillance. *Transfusion* 2021. <https://doi.org/10.1111/trf.16555> (trf.16555).
19. Yao L, Wang G-L, Shen Y, et al. Persistence of antibody and cellular immune responses in COVID-19 patients over nine months after Infection. *J Infect Dis* 2021. <https://doi.org/10.1093/infdis/jiab255>.
20. Wisnivesky JP, Stone K, Bagiella E, et al. Long-term persistence of neutralizing antibodies to SARS-CoV-2 following infection. *J Gen Intern Med* 2021. <https://doi.org/10.1007/s11606-021-07057-0>.
21. Dispinseri S, Secchi M, Pirillo MF, et al. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival. *Nat Commun* 2021;12:2670.
22. Goto A, Go H, Miyakawa K, et al. Sustained Neutralizing Antibodies 6 Months Following Infection in 376 Japanese COVID-19 Survivors. *Front Microbiol* 2021;12:661187.
23. Orth-Höller D, Eigentler A, Stiasny K, Weseslindtner L, Möst J. Kinetics of SARS-CoV-2 specific antibodies (IgM, IgA, IgG) in non-hospitalized patients four months following infection. *J Infect* 2021;82:282–327.
24. Le Bert N, Clapham HE, Tan AT, et al. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection. *J Exp Med* 2021;218. <https://doi.org/10.1084/jem.20202617>.
25. Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science* 2021;371. <https://doi.org/10.1126/science.abf4063>.
26. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. *Cell* 2020;181:1489–501, e15.
27. Peng Y, Mentzer AJ, Liu G, et al. Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19. *Nat Immunol* 2020;21:1336–45.
28. Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. *Cell* 2020;183:996–1012, e19.
29. Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T Cell immunity in convalescent individuals with asymptomatic or mild COVID-19. *Cell* 2020;183:158–68, e14.
30. Peluso MJ, Deitchman AN, Torres L, et al. Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms. *Cell Rep* 2021:109518.
31. Bilich T, Nelde A, Heitmann JS, et al. T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals. *Sci Transl Med* 2021;13. <https://doi.org/10.1126/scitranslmed.abf7517>.
32. Jiang X-L, Wang G-L, Zhao X-N, et al. Lasting antibody and T cell responses to SARS-CoV-2 in COVID-19 patients three months after infection. *Nat Commun* 2021;12:897.
33. Cho A, Muecksch F, Schaefer-Babajew D, et al. Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination. *Nature* 2021. <https://doi.org/10.1038/s41586-021-04060-7>.
34. Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. *Nature* 2020;584:457–62.
35. Stokel-Walker C. What we know about covid-19 reinfection so far. *BMJ* 2021;372:n99.
36. Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination - kentucky, May-June 2021. *MMWR Morb Mortal Wkly Rep* 2021;70:1081–3.
37. Grifoni A, Sidney J, Vita R, et al. SARS-CoV-2 human T cell epitopes: Adaptive immune response against COVID-19. *Cell Host Microbe* 2021;29:1076–92.
38. Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. *bioRxiv* 2020. <https://doi.org/10.1101/2020.12.08.416750>.
39. Kobischke M, Traugott MT, Medits I, et al. Dynamics of CD4 T Cell and antibody responses in COVID-19 patients with different disease severity. *Front Med* 2020;7:592629.
40. Boppana S, Qin K, Files JK, et al. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence. *PLoS Pathog* 2021;17:e1009761.
41. Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. *Cell* 2021;184:861–80.



42. Perez-Potti A, Lange J, Buggert M. Deciphering the ins and outs of SARS-CoV-2-specific T cells. *Nat Immunol* 2021;22(1):8–9.
43. Tarke A, Sidney J, Methot N, et al. Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. *Cell Rep Med* 2021;2:100355.
44. Tarke A, Sidney J, Methot N, et al. Negligible impact of SARS-CoV-2 variants on CD4+ and CD8+ T cell reactivity in COVID-19 exposed donors and vaccinees. *bioRxiv* 2021. <https://doi.org/10.1101/2021.02.27.433180>.
45. Lipsitch M, Grad YH, Sette A, Crotty S. Cross-reactive memory T cells and herd immunity to SARS-CoV-2. *Nat Rev Immunol* 2020;20:709–13.
46. Karlsson AC, Humbert M, Buggert M. The known unknowns of T cell immunity to COVID-19. *Sci Immunol* 2020;5. <https://doi.org/10.1126/sciimmunol.abe8063>.
47. Nelde A, Bilich T, Heitmann JS, et al. SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition. *Nat Immunol* 2021;22:74–85.
48. Bacher P, Rosati E, Esser D, et al. Low-Avidity CD4+ T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19. *Immunity* 2020;53:1258–71. e5.
49. Ogbe A, Kronsteiner B, Skelly DT, et al. T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. *Nat Commun* 2021;12:2055.
50. Klasse PJ, Nixon DF, Moore JP. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. *Sci Adv* 2021;7. <https://doi.org/10.1126/sciadv.abe8065>.
51. Abbasi J. SARS-CoV-2 variant antibodies wane 6 months after vaccination. *JAMA* 2021;326:901.
52. Jung J, Sung H, Kim S-H. Covid-19 breakthrough infections in vaccinated health care workers. *N Engl J Med* 2021;385. <https://doi.org/10.1056/NEJMc2113497>.
53. Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. *N Engl J Med* 2021. <https://doi.org/10.1056/NEJMoa2114583>.
54. Pilishvili T, Gierke R, Fleming-Dutra KE, et al. Effectiveness of mRNA Covid-19 vaccine among U.S. Health Care Personnel. *N Engl J Med* 2021. <https://doi.org/10.1056/NEJMoa2106599>.
55. Thomas SJ, Moreira ED Jr, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. *N Engl J Med* 2021. <https://doi.org/10.1056/NEJMoa2110345>.
56. Ke R, Martinez PP, Smith RL, et al. Longitudinal analysis of SARS-CoV-2 vaccine breakthrough infections reveal limited infectious virus shedding and restricted tissue distribution. *medRxiv* 2021. <https://doi.org/10.1101/2021.08.30.21262701>.
57. Doria-Rose N, Suthar MS, Makowski M, et al. Antibody Persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19. *N Engl J Med* 2021;384:2259–61.
58. Terpos E, Trougakos IP, Karalis V, et al. Kinetics of anti-SARS-CoV-2 antibody responses 3 months post complete vaccination with BNT162b2; a prospective study in 283 health workers. *Cells* 2021;10:1942.
59. Stock PG, Henrich TJ, Segev DL, Werbel WA. Interpreting and addressing suboptimal immune responses after COVID-19 vaccination in solid-organ transplant recipients. *J Clin Invest* 2021;131. <https://doi.org/10.1172/JCI151178>.
60. Caballero-Marcos A, Salcedo M, Alonso-Fernández R, et al. Changes in humoral immune response after SARS-CoV-2 infection in liver transplant recipients compared to immunocompetent patients. *Am J Transplant* 2021;21:2876–84.
61. Favà A, Donadeu L, Sabé N, et al. SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. *Am J Transplant* 2021;21:2749–61.
62. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. *Transplantation* 2021;105:37–55.
63. Herrera S, Colmenero J, Pascal M, et al. Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients. *Am J Transplant* 2021. <https://doi.org/10.1111/ajt.16768>.
64. Miele M, Busà R, Russelli G, et al. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients. *Am J Transplant* 2021;21:2919–21.
65. Boyarsky BJ, Werbel WA, Avery RK, et al. Antibody response to 2-Dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients. *JAMA* 2021;325:2204–6.
66. Ou MT, Boyarsky BJ, Motter JD, et al. Safety and reactogenicity of 2 Doses of SARS-CoV-2 vaccination in solid organ transplant recipients. *Transplantation* 2021;105:2170–4.
67. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single Dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. *JAMA* 2021;325:1784–6.
68. Sattler A, Schrezenmeier E, Weber UA, et al. Impaired humoral and cellular immunity after SARS-CoV-2 BNT162b2 (tozinameran) prime-boost vaccination in kidney transplant recipients. *J Clin Invest* 2021;131. <https://doi.org/10.1172/JCI150175>.
69. Werbel WA, Boyarsky BJ, Ou MT, et al. Safety and immunogenicity of a third Dose of SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. *Ann Intern Med* 2021;174:1330–2.
70. Alejo JL, Mitchell J, Chiang TP-Y, et al. Antibody response to a fourth Dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series. *Transplantation* 2021. <https://doi.org/10.1097/TP.0000000000003934>.
71. Monin L, Laing AG, Muñoz-Ruiz M, et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. *Lancet Oncol* 2021;22:765–78.
72. Massarweh A, Eliakim-Raz N, Stemmer A, et al. Evaluation of seropositivity following BNT162b2 Messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer. *JAMA Oncol* 2021;7:1133–40.
73. Greenberger LM, Saltzman LA, Senefeld JW, Johnson PW, DeGennaro LJ, Nichols GL. Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies. *Cancer Cell* 2021. <https://doi.org/10.1016/j.ccell.2021.09.001>.
74. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. *Clin Microbiol Infect* 2021. <https://doi.org/10.1016/j.cmi.2021.06.036>.
75. Peluso MJ, Munter SE, Lynch KL, et al. Discordant virus-specific antibody levels, antibody neutralization capacity, and T-cell Responses Following 3 Doses of SARS-CoV-2 vaccination in a patient with connective tissue disease. *Open Forum Infect Dis* 2021;8:ofab393.
76. Haberman RH, Herati R, Simon D, et al. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in

- immune-mediated inflammatory disease. *Ann Rheum Dis* 2021;80:1339–44.
77. Simon D, Tascilar K, Fagni F, et al. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases. *Ann Rheum Dis* 2021;80:1312–6.
  78. Apostolidis SA, Kakara M, Painter MM, et al. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy. *Nat Med* 2021. <https://doi.org/10.1038/s41591-021-01507-2>.
  79. Sabatino JJ, Mittl K, Rowles W, et al. Impact of multiple sclerosis disease-modifying therapies on SARS-CoV-2 vaccine-induced antibody and T cell immunity. *medRxiv* 2021. doi:10.1101/2021.09.10.21262933
  80. Sormani MP, Inglese M, Schiavetti I, et al. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies. *EBioMedicine* 2021:103581.
  81. Disanto G, Sacco R, Bernasconi E, et al. Association of disease-modifying treatment and anti-CD20 infusion timing with humoral response to 2 SARS-CoV-2 vaccines in patients with multiple sclerosis. *JAMA Neurol* 2021. <https://doi.org/10.1001/jamaneurol.2021.3609>.
  82. Moor MB, Suter-Riniker F, Horn MP, et al. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study. *Lancet Rheumatol* 2021. [https://doi.org/10.1016/S2665-9913\(21\)00251-4](https://doi.org/10.1016/S2665-9913(21)00251-4).
  83. Schmidt T, Klemis V, Schub D, et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. *Am J Transplant* 2021. <https://doi.org/10.1111/ajt.16818>.
  84. Hall VG, Ferreira VH, Ierullo M, et al. Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. *Am J Transplant* 2021. <https://doi.org/10.1111/ajt.16766>.
  85. Esmaili S, Abbasi MH, Abolmaali M, et al. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD. *BMC Neurol* 2021;21:183.
  86. Spinelli MA, Lynch KL, Yun C, et al. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study. *Lancet HIV* 2021;8:e334–41. [https://doi.org/10.1016/s2352-3018\(21\)00072-2](https://doi.org/10.1016/s2352-3018(21)00072-2).
  87. Mondì A, Cimini E, Colavita F, et al. COVID-19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS-CoV-2. *J Med Virol* 2021;93:1796–804.
  88. Papalini C, Paciosi F, Schiaroli E, et al. Seroprevalence of anti-SARS-CoV2 antibodies in Umbrian persons living with HIV. *Mediterr J Hematol Infect Dis* 2020;12. <https://doi.org/10.4084/MJHID.2020.080>.
  89. Liu Y, Xiao Y, Wu S, et al. People Living with HIV Easily lose their Immune Response to SARS-CoV-2: Result From A Cohort of COVID-19 Cases in Wuhan, China. 2021. doi:10.21203/rs.3.rs-543375/v1
  90. Woldemeskel BA, Karaba AH, Garliss CC, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with HIV. *Clin Infect Dis* 2021. <https://doi.org/10.1093/cid/ciab648>.
  91. Ruddy JA, Boyarsky BJ, Bailey JR, et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV. *AIDS* 2021. <https://doi.org/10.1097/QAD.0000000000003017>.
  92. Buechler MB, Newman LP, Chohan BH, Njoroge A, Wamalwa D, Farquhar C. T cell anergy and activation are associated with suboptimal humoral responses to measles revaccination in HIV-infected children on anti-retroviral therapy in Nairobi, Kenya. *Clin Exp Immunol* 2015;181:451–6.
  93. Avelino-Silva VI, Miyaji KT, Hunt PW, et al. CD4/CD8 Ratio and KT ratio predict yellow fever vaccine immunogenicity in HIV-infected patients. *PLoS Negl Trop Dis* 2016;10:e0005219.
  94. Colin de Verdiere N, Durier C, Samri A, et al. Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients. *AIDS* 2018;32:2291–9.
  95. Parmigiani A, Alcaide ML, Freguja R, et al. Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. *PLoS One* 2013;8:e79816.
  96. van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. *AIDS Rev* 2009;11:157–64.
  97. Kroon FP, van Dissel JT, Labadie J, van Loon AM, van Furth R. Antibody response to diphtheria, tetanus, and poliomyelitis vaccines in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. *Clin Infect Dis* 1995;21:1197–203.
  98. Zheng M, Gao Y, Wang G, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol* 2020;17:533–5.
  99. Zheng H-Y, Zhang M, Yang C-X, et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. *Cell Mol Immunol* 2020;17:541–3.
  100. Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. *J Infect* 2020;80:607–13.
  101. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, et al. Hematological findings and complications of COVID-19. *Am J Hematol* 2020;95:834–47.
  102. Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis* 2020;71:762–8.
  103. Li CK-F, Wu H, Yan H, et al. T cell responses to whole SARS coronavirus in humans. *J Immunol* 2008;181:5490–500.
  104. Lavillegrand J-R, Garnier M, Spaeth A, et al. Elevated plasma IL-6 and CRP levels are associated with adverse clinical outcomes and death in critically ill SARS-CoV-2 patients: inflammatory response of SARS-CoV-2 patients. *Ann Intensive Care* 2021;11:9.
  105. Sharifpour M, Rangaraju S, Liu M, et al. C-Reactive protein as a prognostic indicator in hospitalized patients with COVID-19. *PLoS One* 2020;15:e0242400.
  106. Tobias Herold MD, Arnreich C, Hellmuth JC, Matthias Klein MD, Tobias Weinberger MD. Level of IL-6 predicts respiratory failure in hospitalized symptomatic COVID-19 patients. [https://www.allergy.org.au/images/stories/about/attach-IL-6\\_as\\_a\\_-marker\\_of\\_outcome\\_in\\_COVID-19.pdf](https://www.allergy.org.au/images/stories/about/attach-IL-6_as_a_-marker_of_outcome_in_COVID-19.pdf)
  107. Del Valle DM, Kim-Schulze S, Huang H-H, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med* 2020;26:1636–43.
  108. Lucas C, Wong P, Klein J, et al. Longitudinal analyses reveal immunological misfiring in severe COVID-19. *Nature* 2020;584:463–9.
  109. Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. *Nat Med* 2020;26:1623–35.
  110. Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. *Emerg Microbes Infect* 2020;9:1123–30.

111. Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. *J Infect* 2020;81:e6–e12. 1141
112. Lagunas-Rangel FA. Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. *J Med Virol* 2020;92:1733–4. 1142
113. Wang F, Nie J, Wang H, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. *J Infect Dis* 2020;221:1762–9. 1143
114. Shi Y, Wang Y, Shao C, et al. COVID-19 infection: the perspectives on immune responses. *Cell Death Differ* 2020;27:1451–4. 1144
115. Bonny TS, Patel EU, Zhu X, et al. Cytokine and chemokine levels in coronavirus disease 2019 convalescent plasma. *Open Forum Infect Dis* 2021;8:ofaa574. 1145
116. Ong SWX, Fong S-W, Young BE, et al. Persistent symptoms and association with inflammatory cytokine signatures in recovered coronavirus disease 2019 patients. *Open Forum Infect Dis* 2021;8:ofab156. 1146
117. Tenorio AR, Zheng Y, Bosch RJ, et al. Soluble markers of inflammation and coagulation but not T-cell activation predict non-AIDS-defining morbid events during suppressive antiretroviral treatment. *J Infect Dis* 2014;210:1248–59. 1147
118. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. *PLoS Pathog* 2014;10:e1004078. 1148
119. Nalbandian A, Sehgal K, Gupta A, et al. Post-acute COVID-19 syndrome. *Nat Med* 2021. <https://doi.org/10.1038/s41591-021-01283-z>. 1149
120. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature* 2021;594:259–64. 1150
121. Ayoubkhani D. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK - Office for National Statistics 2021:Accessed April 7, 2021 <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocial-care/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021>. 1151
122. Blomberg B, Mohn KG-I, Brokstad KA, et al. Long COVID in a prospective cohort of home-isolated patients. *Nat Med* 2021. <https://doi.org/10.1038/s41591-021-01433-3>. 1152
123. Horton DB, Barrett ES, Roy J, et al. Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. *J Infect Dis* 2021. <https://doi.org/10.1093/infdis/jiab411>. 1153
124. Hu F, Chen F, Ou Z, et al. A compromised specific humoral immune response against the SARS-CoV-2 receptor-binding domain is related to viral persistence and periodic shedding in the gastrointestinal tract. *Cell Mol Immunol* 2020;17:1119–25. 1154
125. Augustin M, Schommers P, Stecher M, et al. Post-COVID syndrome in non-hospitalised patients with COVID-19: a longitudinal prospective cohort study. *Lancet Reg Health Eur* 2021;6:100122. 1155
126. Talla A, Vasaikar SV, Lemos MP, et al. Longitudinal immune dynamics of mild COVID-19 define signatures of recovery and persistence. *bioRxiv* 2021. <https://doi.org/10.1101/2021.05.26.442666>. 1156
127. Peluso MJ, Lu S, Tang AF, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis* 2021. <https://doi.org/10.1093/infdis/jiab490>. 1157
128. Hunt PW, Sinclair E, Rodriguez B, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. *J Infect Dis* 2014;210:1228–38. 1158
129. Gianella S, Chaillon A, Mutlu EA, et al. Effect of cytomegalovirus and Epstein-Barr virus replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals. *AIDS* 2017;31:2059–67. 1159
130. Sacchi MC, Tamiazzo S, Stobbione P, et al. SARS-CoV-2 infection as a trigger of autoimmune response. *Clin Transl Sci* 2021;14:898–907. 1160
131. Guilmot A, Maldonado Sloopjes S, Sellimi A, et al. Immune-mediated neurological syndromes in SARS-CoV-2-infected patients. *J Neurol* 2021;268:751–7. 1161
132. Song E, Bartley CM, Chow RD, et al. Divergent and self-reactive immune responses in the CNS of COVID-19 patients with neurological symptoms. *Cell Rep Med* 2021;2:100288. 1162
133. Seele J, Waterboer T, Hippchen T, et al. Persistent symptoms in adult patients one year after COVID-19: a prospective cohort study. *Clin Infect Dis* 2021. <https://doi.org/10.1093/cid/ciab611>. 1163
134. Peluso MJ, Thomas IJ, Munter SE, Deeks SG, Henrich TJ. Lack of antinuclear antibodies in convalescent COVID-19 patients with persistent symptoms. *Clin Infect Dis* 2021. <https://doi.org/10.1093/cid/ciab890>. 1164
135. Avanzato VA, Matson MJ, Seifert SN, et al. Case study: prolonged infectious SARS-CoV-2 shedding from an asymptomatic immunocompromised individual with cancer. *Cell* 2020;183:1901–12, e9. 1165
136. Choi B, Choudhary MC, Regan J, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *N Engl J Med* 2020;383:2291–3. 1166
137. Zheng S, Fan J, Yu F, et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. *BMJ* 2020;369:m1443. 1167
138. O'Donnell JS, Chappell KJ. Chronic SARS-CoV-2, a cause of post-acute COVID-19 sequelae (Long-COVID)? *Front Microbiol* 2021;12:724654. 1168
139. Oliva A, Miele MC, Di Timoteo F, et al. Persistent systemic microbial translocation and intestinal damage during coronavirus disease-19. *Front Immunol* 2021;12:708149. 1169
140. ÁH Borges, JL O'Connor, Phillips AN, et al. Interleukin 6 is a stronger predictor of clinical events than high-sensitivity c-reactive protein or D-dimer during HIV infection. *J Infect Dis* 2016;214:408–16. 1170
141. Hsu DC, Ma YF, Hur S, et al. Plasma IL-6 levels are independently associated with atherosclerosis and mortality in HIV-infected individuals on suppressive antiretroviral therapy. *AIDS* 2016;30:2065–74. 1171
142. Wada NI, Bream JH, Martínez-Maza O, et al. Inflammatory biomarkers and mortality risk among HIV-suppressed men: a multisite prospective cohort study. *Clin Infect Dis* 2016;63:984–90. 1172
143. Freeman ML, Mudd JC, Shive CL, et al. CD8 T-Cell expansion and inflammation linked to CMV coinfection in ART-treated HIV infection. *Clin Infect Dis* 2016;62:392–6. 1173
144. Freeman ML, Lederman MM, Gianella S. Partners in crime: the role of CMV in immune dysregulation and clinical outcome during HIV infection. *Curr HIV/AIDS Rep* 2016;13:10–9. 1174
145. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. *Clin Infect Dis* 2017;64:87–91. 1175
146. Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause 1176

- and cardiovascular disease-related mortality in the United States. *PLoS One* 2011;6:e16103.
147. Wang H, Peng G, Bai J, et al. Cytomegalovirus infection and relative risk of cardiovascular disease (Ischemic Heart Disease, Stroke, and Cardiovascular Death): a meta-analysis of prospective studies up to 2016. *J Am Heart Assoc* 2017;6. <https://doi.org/10.1161/JAHA.116.005025>.
148. Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol* 2004;203:631–7.
149. Salamanna F, Maglio M, Landini MP, Fini M. Body localization of ACE-2: on the trail of the keyhole of SARS-CoV-2. *Front Med* 2020;7:594495.
150. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19. *N Engl J Med* 2020;382:1653–9.
151. Wu G, Zuck P, Goh SL, et al. Gag p24 is a marker of HIV expression in tissues and correlates with immune response. *J Infect Dis* 2021. <https://doi.org/10.1093/infdis/jiab121>.
152. McManus WR, Bale MJ, Spindler J, et al. HIV-1 in lymph nodes is maintained by cellular proliferation during antiretroviral therapy. *J Clin Invest* 2019;129:4629–42.
153. Nguyen S, Deleage C, Darko S, et al. Elite control of HIV is associated with distinct functional and transcriptional signatures in lymphoid tissue CD8+ T cells. *Sci Transl Med* 2019;11. <https://doi.org/10.1126/scitranslmed.aax4077>.
154. Patro SC, Brandt LD, Bale MJ, et al. Combined HIV-1 sequence and integration site analysis informs viral dynamics and allows reconstruction of replicating viral ancestors. *Proc Natl Acad Sci U S A* 2019;116:25891–9.
155. Lee E, von Stockenström S, Morcilla V, et al. Impact of antiretroviral therapy duration on HIV-1 infection of T Cells within anatomic sites. *J Virol* 2020;94. <https://doi.org/10.1128/JVI.01270-19>.
156. Henrich TJ, Hatano H, Bacon O, et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study. *PLoS Med* 2017;14:e1002417.
157. Khoury G, Fromentin R, Solomon A, et al. Human immunodeficiency virus persistence and T-Cell activation in blood, rectal, and lymph node tissue in human immunodeficiency virus-infected individuals receiving suppressive antiretroviral therapy. *J Infect Dis* 2017;215:911–9.
158. Telwatte S, Kim P, Chen T-H, et al. Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents. *AIDS* 2020;34:2013–24.
159. Telwatte S, Lee S, Somsouk M, et al. Gut and blood differ in constitutive blocks to HIV transcription, suggesting tissue-specific differences in the mechanisms that govern HIV latency. *PLoS Pathog* 2018;14:e1007357.
160. Yukl SA, Sinclair E, Somsouk M, et al. A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells. *AIDS* 2014;28:439–42.
161. Hatano H, Somsouk M, Sinclair E, et al. Comparison of HIV DNA and RNA in gut-associated lymphoid tissue of HIV-infected controllers and noncontrollers. *AIDS* 2013;27:2255–60.
162. Busman-Sahay K, Starke CE, Nekorchuk MD, Estes JD. Eliminating HIV reservoirs for a cure: the issue is in the tissue. *Curr Opin HIV AIDS* 2021;16:200–8.
163. Moysi E, Del Rio Estrada PM, Torres-Ruiz F, Reyes-Terán G, Koup RA, In Petrovas C. Situ characterization of human lymphoid tissue immune cells by multispectral confocal imaging and quantitative image analysis; implications for HIV reservoir characterization. *Front Immunol* 2021;12:683396.
164. Vasquez JJ, Hussien R, Aguilar-Rodriguez B, et al. Elucidating the burden of HIV in tissues using multiplexed immunofluorescence and in situ hybridization: methods for the single-cell phenotypic characterization of cells harboring HIV in situ. *J Histochem Cytochem* 2018;66:427–46.
165. McBrien JB, Mavigner M, Franchitti L, et al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells. *Nature* 2020;578:154–9.